



ELSEVIER

Contents lists available at ScienceDirect

Pharmacological Reports

journal homepage: www.elsevier.com/locate/pharep

Original research article

Hypoestrogenism alters mood: Ketamine reverses depressive-like behavior induced by ovariectomy in rats

Q1 Sonia Fatima da Silva Moreira^{a,c,d}, Ellen A. Nunes^{a,e}, Jonnsin Kuo^a, Isabel Cristina de Macedo^{a,e}, Alexis Muchale^a, Carla de Oliveira^{a,c}, Vanessa L. Scarabelot^{a,e}, Paulo Ricardo Marques Filho^{a,c}, Liciane F. Medeiros^{a,e}, Wolnei Caumo^{a,c}, Iraci L.S. Torres^{a,b,c,*}

^aPharmacology of Pain and Neuromodulation Laboratory: Animals Models, Department of Pharmacology, Universidade Federal do Rio Grande do Sul Institute of Basic Health Sciences, Porto Alegre, Brazil

^bAnimal Experimentation Unit and Graduate Research Group, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

^cGraduate Program in Medical Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

^dFaculdade de Medicina, Instituto de Ciências da Saúde, Universidade Federal do Pará, Belém, Brazil

^eGraduate Program in Biological Sciences: Physiology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

ARTICLE INFO

Article history:

Received 20 January 2015

Received in revised form 19 June 2015

Accepted 23 June 2015

Available online xxx

Keywords:

Menopause

Depression

Ketamine

Female rats

Aging

ABSTRACT

Background: Estrogen deficiency is associated with the onset of depressive and anxiety symptoms, cognitive impairment, and adverse consequences. We investigated depressive-like behaviors in ovariectomized rats and ketamine's effect on this behavior.

Methods: Twenty-eight female Wistar adult rats were initially divided into two groups: ovariectomized (OVX) and sham surgery (SHAM). Hormonal status was verified by vaginal cytology, and the rats were subjected to a forced swimming (FS) test 18 days post-surgery, an open field (OF) test 28 days post-surgery, and an elevated plus maze (EPM) test 38 days post-surgery (Experiment 1). In addition, the effect of ketamine on depressive-like behavior of the female rats was evaluated (Experiment 2).

Results: OVX group exhibited anxiety-like behavior on EPM test (lower time spent and fewer entries in the open arms), without any difference in performance in the OF test. OVX rats showed depressive-like behavior (higher time of immobility) than SHAM rats in FS test. The SHAM group showed signs of hypoestrogenism (anestrus) at six months of age. Moreover, ketamine was able to reverse depressive-like behavior in the FS retest in both groups (OVX and SHAM).

Conclusion: Similar to the literature, we showed the antidepressant effect of ketamine in depressive female rats which was induced by ovariectomy; including in female rats submitted to sham surgery that interestingly presented a premature menopausal.

© 2015 Published by Elsevier Sp. z o.o. on behalf of Institute of Pharmacology, Polish Academy of Sciences.

Introduction

Q2 Menopause is a physiological process caused by the loss of ovarian follicular activity leading to a decrease in the production of estrogens. Hypoestrogenism can cause a variety of physiological and psychological disorders such as changes in the menstrual cycle, vasomotor and genital symptoms, sleep problems, mood swings, and impaired cognitive function [1,2]. Age, menopausal status, chronic diseases and socio-demographic characteristics (income,

ethnicity and educational level) have been identified as predictors of the frequency and severity of menopausal symptoms [2,3].

Data from two cohort studies in the United States showed increased risk of depression in women who enter menopausal transition [4,5]. However, the mechanisms responsible for the development of depression in perimenopausal women remain unclear [6,7]. On the other hand, Díaz-Véliz et al. suggest that ovarian hormones modulate anxiety levels and cognitive functions [8]. Anxiety may be a precursor for depression development [9] or may be accompanied by symptoms of depression [10], thus, it is important to consider equally anxiety and depression symptoms when investigating factors that may affect mood, such as hormonal status [11,12].

* Corresponding author.

E-mail address: iracitorres@gmail.com (Iraci L.S. Torres).

Depressive and anxious symptoms can significantly reduce the quality of life of postmenopausal women [13]. The mechanisms that lead to the emergence of these symptoms in the menopausal transition are not well understood, and even the pathophysiology of depressive disorders has been widely debated. The monoamine theory posits that depression is caused by a decreased function of monoamines in the brain, and antidepressant drugs are designed to increase the supply of these substances by inhibiting reuptake (serotonin and norepinephrine reuptake inhibitors) or degradation (monoamine oxidase inhibitors) [14]. However, the long time to the onset of the therapeutic action and the low rates of remission has encouraged the search for more effective drugs. The observation that small doses of ketamine produce a rapid and transient antidepressant effect increased the interest in neurobiological systems that were not explored in depression [15]. Ketamine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist used in human and veterinary medicine, primarily for the induction and maintenance of general anesthesia. Berman et al. published the first report of ketamine's therapeutic effects on major depressive disorder [15]. After this randomized controlled trial (RCT), many studies provided evidence that a single, intravenous (IV), subanesthetic dose of ketamine may relieve depressive symptoms within hours [16]. Garcia et al. suggest that the increase of hippocampal brain-derived neurotrophic factor (BDNF) protein levels induced by ketamine might be necessary to produce a rapid onset of antidepressant action [17]. Another study from the same laboratory demonstrated that Ketamine alters behavior and decreases BDNF levels in the rat brain as a function of time after drug administration, suggesting that the effects of ketamine on behavior and BDNF levels are related to the time at which they were evaluated after administration of the drug [18].

To understand the pathophysiology of anxiety and depression disorders associated with the decline of endogenous estrogen levels and devise interventions aimed at attenuating these symptoms, it is very important to establish and study animal models of menopause. This study investigated depressive-like and anxiety-like behaviors and cognitive performance in ovariectomized rats and ketamine's effect on performance on a forced swimming test.

Materials and methods

Animals

Twenty-eight female Wistar rats (90 days old, 200–300 g) were randomized by weight and housed in cages of polypropylene material (49 cm × 34 cm × 16 cm). They were housed four per cage and maintained with food and water available ad libitum on a 12 h light/dark cycle (lights on at 7:00 AM, and lights off at 7:00 PM) in a temperature-controlled environment (22 ± 2 °C). The animals were initially distributed into two groups: ovariectomized (OVX) and false surgery (SHAM) and subjected to the forced swimming test (FS) at 18th day post-surgery, open field test (OF) at 28th day post-surgery, and elevated plus maze test (EPM) at 38th day post-surgery. When the animals reached 180 days old, each group was subdivided into two more groups, which received ketamine or vehicle and were again subjected to the forced swimming test. The rats were handled for seven days prior to the experiments and remained in the laboratory for at least 30 min before being submitted to each test. All experiments and procedures were approved by the Institutional Animal Care and Use Committee (GPPG-HCPA protocol No. 110586) and were compliant with Brazilian guidelines involving the use of animals in research (Law N°. 11.794). Additionally, all efforts were made to minimize suffering, pain and discomfort of the animals, as well as to reduce the number of animals.

Surgical procedures

One set of Wistar female rats underwent ovariectomy (surgical removal of the ovaries) and the other set underwent SHAM surgery (opening of the abdominal cavity and sewing it back). At 90 days of age, the rats were anesthetized with ketamine (80 mg/kg, *ip*; Syntec, Brazil) and Xylazine (20 mg/kg, *ip*; Sespo, Brazil) and underwent bilateral ovariectomy. The surgery consisted of a transversal dorsolateral incision of skin, between the last rib and pelvis and muscle dissection in order to expose the abdominal cavity. The ovary is located in a fat pad beneath the muscles. The periovarian fat was grasped to lift and exteriorize the ovary. The fallopian tube was crushed and ligated, and the ovary was removed by cutting above the clamped area. The muscle and the skin incision were closed with poligalactin and nylon suture. This procedure was repeated at the other side for bilateral ovariectomy. In SHAM surgery, rats underwent the same incisions, the ovaries and fallopian tubes were exposed and then put back in the abdominal cavity and the muscle and skin were closed. To reduce pain, all rats received dipyrone (25 mg/kg *ip*) after surgery, and recovered for 10 days.

Vaginal smear

Ten days after surgery, vaginal smear was daily obtained in both groups to verify hormonal status. Samples were obtained and analyzed as described by Goldman et al. [19].

Behavioral tests

Locomotor activity assessed by open field (OF) test

The behavioral assessment was performed in a varnished wood cage, measuring 60 cm × 40 cm × 50 cm with a glass front wall. The floor was covered with linoleum and divided up with dark lines: 12 squares of 13 cm × 13 cm each. The rats were gently placed in the left back corner and allowed to explore the surroundings for 5 min. The number of line crossings was taken as a measure of locomotor activity [20]. Rearing was defined as the moment the rat rose up on its hind legs, ending when one or both front paws touched the floor again [21], being evaluated as exploratory activity [22]. Grooming was defined as licking/washing of the head and body; it was assessed as a biological function of caring for the surface of the body [23]. The start of a trial occurred immediately after the rat was placed in the environment for scoring purposes. In this test, the animal was recorded as entering a new area when all four paws crossed the boundary into a different, marked-out area. Five measures were taken during the five-min test sessions: latency to leave the first quadrant (time in seconds); number of line crossings (i.e. horizontal activity), outer and inner crossings; number of rearing behaviors (i.e. vertical activity); grooming (time in seconds); and number of fecal boluses. The box was thoroughly cleaned using 70% alcohol between each trial.

Anxiety-like behavior assessed by elevated plus-maze (EPM) test

The elevated plus-maze test was used to evaluate anxiety-like behavioral state. The maze was made of black PVC and elevated to a height of 50 cm above floor level. The apparatus included two open arms and two closed arms (50 cm × 40 cm × 10 cm), which extended from a common central platform (10 cm × 10 cm). The animal was placed in the central area of the EPM, facing one of the closed arms. Next, the following behavioral measures were recorded during the five-min test sessions: number of protected head-dipping movements (PHD); number of non-protected head-dipping movements (NPHD); number of entries in the open arms (EOA); number of entries in the closed arms (ECA); time spent on

160 the open arms (TOA); time spent on the closed arms (TCA); time of
161 grooming and number of rearing. Protected head dips involved
162 dipping the head over the sides of the maze from within the central
163 platform or a closed arm, whereas non-protected head dips were
164 considered to occur when the animal dipped its head over the sides
165 of the maze while on an open arm. In the EPM, entering a new area
166 was recorded when all four paws crossed onto a new arm or into
167 the central area [24]. After each test, the apparatus was cleaned
168 thoroughly to remove any animal scent.

169 Depressive-like behavior assessed by forced swimming (FS) test

170 The forced swimming test involved three phases: training, test
171 and retest (under drug influence). A glass square tank (dimensions
172 40 cm × 40 cm × 52 cm, divided into four squares of 20 cm ×
173 20 cm to fit four rats) was filled with water (22–25 °C) to a depth of
174 35 cm, on such a way that the rats' tail could not touch the bottom
175 of the tank. For the first exposure, the rats were placed into
176 water for 15 min (training session). 24 h later, the animals were
177 again placed in the water for a 5-min session (test session). The
178 immobility time of rats was recorded in seconds, considering total
179 immobility and/or movements to keep the head out of the water
180 with no intention of escaping [25]. After the trial, rats were dried
181 using soft towels and hair dryer, if necessary.

182 Experimental design

183 Experiment 1

184 Eighteen days after surgery (P108), groups OVX and SHAM were
185 subjected to the sequence of FS, OF, and EPM tests. The tests were
186 separate at least for one week between them. All female rats were
187 submitted to all tests one by one.

188 Experiment 2

189 At P180, both groups (OVX and SHAM) were subdivided into
190 two more groups that received ketamine (10 mg/kg, *ip* [17,26];
191 Cetamin[®], Syntec, Brazil) (SHAM-K and OVX-K) or vehicle (SHAM-
192 V and OVX-V, saline, *ip*), and were subjected to FST (retest session)
193 30 min after the administration. All female rats were submitted to
194 all tests one by one.

195 Statistical analysis

196 All data are presented as mean ± SEM. All analyses were
197 performed using the Statistical Package for the Social Science (SPSS)
198 software version 18.0. The normality test was performed by
199 Kolmogorov-Smirnov, and the data presented normal distribution.
200 Unpaired and paired Student's *t* tests were used to compare groups at




Fig. 1. Diestrus period of the oestrus cycle of female rats (the presence of diffuse few leukocytes).

201 the same age and to compare intragroup analysis (P108 and p180),
202 respectively; and one-way ANOVA followed by Student–Newman–
203 Keuls (SNK) after ketamine administration. Critical significance level
204 used for all comparisons was 5%.

205 Results

206 Experiment 1

207 The acyclic vaginal smears [void of nucleated (proestrus) cells]
208 occurred in all ovariectomized rats (OVX), as verified since the
209 beginning of vaginal smears procedures, 10 days after surgery, and
210 continuing up to the end of the experiments (Fig. 1). SHAM group
211 presented normal estrous cycling in the first 60 days after surgery.
212 In addition, we did not observe any difference in the swimming
213 time between SHAM and OVX; however, OVX group showed
214 increased immobility time in the FS test as compared to SHAM
215 group (Student's *t* test, $p > 0.05$ and $p < 0.05$, respectively; Fig. 2,
216 Panels A and B; $n = 14$ per group). In the OF test, there was no
217 significant difference between SHAM and OVX groups in all
218 behaviors analyzed (Student's *t* test, $p > 0.05$, data not shown,
219 $n = 10$ – 11 per group). In the EPM test, OVX group showed
220 decreased time spent on open arms ($p < 0.02$), lower number of
221 entries on open arms ($p < 0.02$) and lower number of NPHD
222 ($p < 0.01$) as compared to SHAM group, suggesting an anxiety-like




Fig. 2. Forced swimming test in Experiment 1. Data expressed as mean ± SEM, $n = 14$ animals/group. Time was expressed in seconds. Panel A: Time of swimming. Panel B: Time of immobility. *OVX was significantly different from SHAM (Student's *t* test, $p < 0.05$).

223 behavior in the OVX female rats (Student's *t* test, Fig. 3, Panels A–C,
224 $n = 10$ – 11 per group).

225 Experiment 2

226 At P180, the SHAM group showing signs of hypoestrogenism as
227 indexed by vaginal smears characterizing precocious menopause,
228 increased immobility time on FS retest suggesting depressive-like
229 behavior (paired Student's *t* test, $p < 0.05$, $n = 5$ – 6 per group,
230 Fig. 4), associated to a strong tendency to be different in the swim
231 time (paired Student's *t* test, $p = 0.05$, $n = 5$ – 6 per group, Fig. 4). In
232 addition, both groups that received ketamine (SHAM-K and OVX-K
233 groups) improved its performance and decreased the immobility
234 time, i.e. ketamine reversed the depression-like behaviors in the FS
235 retest (one-way ANOVA/SNK, $p < 0.05$, $n = 5$ – 6 per group, Fig. 5).

236 Discussion

237 In this study we showed, at the first moment, that ovariecto-
238 mized female rats presented depressive-like and anxiety-like
239 behaviors. It is interesting to note that the OVX female rats showed
240 anxiety-like behavior in the EPM test without any impairment in
241 the locomotion assessed in the OF test. Our findings corroborate
242 previous studies showing the modulatory effects of ovarian

243 hormones upon behavioral indices of anxiety [8,27]. Díaz-Véliz
244 found different effects of diazepam on conditioning avoidance and
245 motor activity in female rats, according to hormonal status
246 [28]. Moreover, the anxiety-like behavior of OVX group on EPM
247 test corroborates Kessler et al.'s studies (in 2005 and 2008) that
248 showed association between depressive and anxiety disorders
249 [10,29]. The estradiol injection, compared to vehicle, subcutaneous-
250 ly or into the hippocampus or amygdala of ovariectomized rats
251 decreases anxiety-like and depression-like behaviors, as reported by
252 Wolf and Frye [27]. These authors also showed that chronic estradiol
253 replacement to aged female rats reduces anxiety-like and depres-
254 sion-like behavior and enhances cognitive performance [30].

255 Interestingly, afterwards three months later, the SHAM surgery
256 group presented the cessation of normal estrous cycling, exhibiting
257 aberrant cycling patterns at 180 days old, including an increase in
258 the number of days per cycle and a decrease in number of vaginal
259 cells, on vaginal smears, followed by persistent diestrus. This result
260 characterized a precocious menopause, and those also presented a
261 depressive-like behavior. The OVX rats remained with similar
262 behavior presented at P108. Moreover, the NMDA receptor
263 antagonist (ketamine) was able to reverse this behavior in both
264 groups evaluated (OVX and SHAM groups).

265 The precocity of the ovarian failure was an unexpected finding,
266 for, in general, female rats only show no estrous cycle when they




Fig. 3. Elevated Plus Maze test in Experiment 1. Data expressed as mean \pm SEM. Panel A: Time spent in the arms was expressed in seconds. Panel B: Number of entries in the arms. Panel C: Number of PDH and NPHD behaviors. PHD: number of protected head dipping. NPHD: number of non-protected head dipping. *OVX different from SHAM group (Student's *t* test; Panel A, $p < 0.02$; Panel B, $p < 0.02$; Panel C, $p < 0.01$).




Fig. 4. Forced swimming test at P108 and P180 in OVX and SHAM groups. Time was expressed in seconds. Data expressed as mean \pm SEM ($n = 5-6$ animals/group). Panel A: Time of immobility. Panel B: Time of swimming. *SHAM group different at P180 from P108 in the immobility time (paired Student's t test, $p < 0.05$).

reach about 12 months [31]. Reproductive senescence in rodents is similar to menopause in several critical aspects, including similar alterations in pulsatile LH release and the LH surge, variability of cycle length prior to acyclicity, and ultimate cessation of hormone cycling. We hypothesized that ovarian and fallopian tubes exposition through the small dorsolateral opening may have accelerated ovaries aging by some mechanism such as trauma or impairment of blood circulation, which possibly elicits irreversible degenerative responses or necrosis in the ovaries cells.

Depressive-like behavior on aged SHAM group was less evident than on OVX group. This finding indicates that depressive-like behavior is present on both, natural or artificial ovarian depletion in female rats, the latter being more evident, probably because of gradual lowering of hormone levels on aging, and this mimics natural menopause in humans. There are several transgenic mice models of ovarian senescence. However, in such cases, fetal development of the reproductive system has been affected and

normal reproductive function has never been achieved [32]. These data suggested the possibility of a new animal model of menopause transition, in which there is a gradual ovarian failure, which can be used in researches on menopause symptoms, more closely mimicking the biology of natural menopause in humans.

Thus, female rats with surgical (OVX) and premature menopause (SHAM) showed depressive-like behavior probably related to hypoestrogenism. These results are consistent with the scientific evidence about neuromodulatory effect of estrogen on mood [6-8,13]. The amygdala and hippocampus are brain regions known to be involved in mood regulation and animal studies have reported that the amygdala has one of the highest densities of estrogen receptors in the brain [33]. Estrada-Camarena et al. studied ovariectomized female Wistar rats, using the FS test, and found that estrogens have antidepressant-like effect characterized by a reduced immobility and increased swimming time and facilitate the action of fluoxetine and desipramine [34,35]. However, these




Fig. 5. Forced swimming test at six months in OVX and SHAM groups under use of ketamine or vehicle. Time was expressed in seconds. Data expressed as mean \pm SEM ($n = 5-6$ animals/group). SHAM-V: rats under sham ovariectomy and vehicle (*ip*); SHAM-K: rats under sham ovariectomy and ketamine (10 mg/kg *ip*); OVX-V: rats under ovariectomy and vehicle (*ip*); OVX-K: rats under ovariectomy and ketamine (10 mg/kg *ip*). *SHAM-K and OVX-K different from SHAM-V and OVX-V groups (one-way ANOVA/SNK, $p < 0.05$).

effects were dependent on the type of estrogen used, and all combinations of estrogens and antidepressants decreased rats' locomotor activity when evaluated in the open field test [34,35].

In the present study, the depressive-like behavior was reversed in both groups (OVX and SHAM) by ketamine, a non-competitive antagonist of the N-methyl D-aspartate receptor (NMDAR) that has been studied as an antidepressant drug in the sub-anesthetic dose. Most of the experimental studies on antidepressant effects of ketamine use male rodents [36]. Carrier and Kabbaj demonstrated that intact female rats are more sensitive than male rats to the antidepressant effects of ketamine [37]. In addition, we used a dose of 10 mg/kg, as described by Garcia et al. [17] and Yang et al. [26], and the ovariectomized rats presented a significant reduction in the immobility time on the forced swimming test. Our finding complements those of Carrier and Kabbaj study, showing a dose-dependent action of ketamine in ovariectomized female rats.

In general, rodent models use stress-induced impairment of hippocampal function to produce the depressive-like behavior and test new antidepressants [38]. Estrogens act through ER α and ER β -receptor subtypes to modulate the transcription of genes, which, in turn, encode a variety of proteins. These proteins include many of the enzymes that play a key role in the synthesis and function of neurotransmitters including serotonin. Estrogens also have multiple effects on dopamine systems, including upregulation of dopamine D1A receptors [39] and increase of dopamine transporters' density [40]. Serotonin hetero-receptors are present in dopamine neurons creating multiple interaction points between estrogens, serotonin and dopamine neurotransmission that may be the link between depression and perimenopause in women with increased vulnerability. Yet, ketamine does not work through the "conventional" antidepressant mono-aminergic targets of serotonin and noradrenaline [41], since this effect is classically based on NMDAR antagonism. Then its action on a model of menopause depressive-like behavior launches new pathways into the study of the pathophysiology of depression in this period of the women's life. It is important to note that the action of estradiol on glutamatergic system, in relation to the lordosis behavior of female rats, has been well established in the works of McCarthy [42]. Thus, we can suggest that the reversion of depressive-like behavior in ovariectomized rats makes a point of the role of glutamate in the depressive symptoms of menopause. The role of progesterone also has to be considered, since studies demonstrated proestrus increases in anxiolytic-like behavior in female rats that were coincident with elevated circulating and hippocampal progesterin concentrations [43]. In addition, it is important to note that previous studies have been demonstrated that ketamine is able to increase some signaling proteins and synapses number and functions in the prefrontal cortex [44]. Other recent study showed that the antidepressant effect of ketamine can be linked to the synthesis of brain-derived neurotrophic factor (BDNF) [45].

It is important to point out an important limitation of our study that was the lack of control group. However, we need to consider that when the female rats were submitted to the SHAM ovariectomy surgery, we did not expect that those animals could present the hypoestrogenism. And, we believed that our results did not suffer any impairment with this decision, and add a new advance to animal model of menopause studies.

In conclusion, this study shows evidences about neuromodulatory effect of estrogen on mood, and ketamine's acute action on depressive-like behavior on a model of menopause. In addition, we observed an interesting finding, the premature induction of animal model of menopause induced by ovarian and fallopian tubes exposition. However, further researches are needed to clarify the mechanisms by which ovarian and fallopian tubes exposition through dorsolateral incisions may have caused precocious ovarian failure in female Wistar rats. Therefore, it is

necessary to development new studies for better understanding about the intrinsic mechanisms related to depressive-like behavior induced by hypoestrogenism, and the involvement different receptor and signaling of the ketamine action.

Conflict of interest

The authors report no conflicts of interest. The authors alone are responsible for the contents and writing of this paper.

Acknowledgements

This study was supported by the following Brazilian funding agencies: National Council for Scientific and Technological Development – CNPq (Dr. I.L.S. Torres, Grant no. 307772/2008-0/2008, Dr. W. Caumo; Medeiros, L.F. Scarabelot, V.L.); PROPESQ/UFRGS/PBIC/CNPq (Muchale, A.); Committee for the Development of Higher Education Personnel – CAPES (Moreira, S.F.S., Oliveira, C.; Marques, P.M.R., Macedo, I.C.); and Graduate Research Group (GPPG) of Hospital de Clínicas de Porto Alegre – HCPA (Dr I.L.S. Torres – Grant 110586).

Doctoral Grant: Postgraduate Program in Medical Sciences at the School of Medicine of the Federal University of Rio Grande do Sul in Inter-institutional PhD Program (Moreira, S.F.S.).

References

- [1] Maki PM, Freeman EW, Greendale GA, Henderson VW, Newhouse PA, Schmidt PJ, et al. Summary of the National Institute on Aging-sponsored conference on depressive symptoms and cognitive complaints in the menopausal transition. *Menopause* 2010;17:815-22.
- [2] Mahajan N, Aggarwal M, Bagga A. Health issues of menopausal women in North India. *J Midlife Health* 2012;3:84-7.
- [3] Pérez-Alcalá I, Sievert LL, Obermeyer CM, Reher DS. Cross cultural analysis of factors associated with age at natural menopause among Latin-American immigrants to Madrid and their Spanish neighbors. *Am J Hum Biol* 2013;25:780-8.
- [4] Bromberger JT, Kravitz HM. Mood and menopause: findings from the Study of Women's Health across the Nation (SWAN) over 10 years. *Obstet Gynecol Clin North Am* 2011;38:609-25.
- [5] Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow L. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. *Arch Gen Psychiatry* 2006;63:385-90.
- [6] Wharton W, Gleason CE, Olson SR, Carlsson CM, Asthana S. Neurobiological underpinnings of the estrogen – mood relationship. *Curr Psychiatry Rev* 2012;8:247-56.
- [7] LaRocco-Cockburn A, Reed SD, Melville J, Croicu C, Russo JE, Inspektor M, et al. Improving depression treatment for women: integrating a collaborative care depression intervention into OB-GYN care. *Contemp Clin Trials* 2013;36:362-70.
- [8] Díaz-Vélez G, Alarcón T, Espinoza C, Dussaubat N, Mora S. Ketanserin and anxiety levels: influence of gender, estrous cycle, ovariectomy and ovarian hormones in female rats. *Pharmacol Biochem Behav* 1997;58:637-42.
- [9] Paul SM. Anxiety and depression: a common neurobiological substrate? *J Clin Psychiatry* 1988;49(Suppl.):13-6.
- [10] Kessler RC, Gruber M, Hetttema JM, Hwang I, Sampson N, Yonkers KA. Comorbid major depression and generalized anxiety disorders in the National Comorbidity Survey follow-up. *Psychol Med* 2008;38:365-74.
- [11] Seeman MV. Psychopathology in women and men: focus on female hormones. *Am J Psychiatry* 1997;154:1641-7.
- [12] Young EA, Korszun A. The hypothalamic-pituitary-gonadal axis in mood disorders. *Endocrinol Metab Clin North Am* 2002;31:63-78.
- [13] Terauchi M, Hiramitsu S, Akiyoshi M, Owa Y, Kato K, Obayashi S, et al. Associations among depression, anxiety and somatic symptoms in peri- and postmenopausal women. *J Obstet Gynaecol Res* 2013;39(5):1007-13.
- [14] Krishnan V, Nestler EJ. The molecular neurobiology of depression. *Nature* 2008;455(7215):894-902.
- [15] Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. *Biol Psychiatry* 2000;47:351-4.
- [16] Naughton M, Clarke G, O'Leary OF, Cryan JF, Dinan TG. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. *J Affect Disord* 2014;156:24-35.
- [17] Garcia LS, Comim CM, Valvassori SS, Réus GZ, Barbosa LM, Andreazza AC, et al. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. *Prog Neuropsychopharmacol Biol Psychiatry* 2008;32:140-4.

- 439 [18] Fraga DB, Réus GZ, Abelaira HM, De Luca RD, Canever L, Pfaffenseller B, et al. Ketamine alters behavior and decreases BDNF levels in the rat brain as a function of time after drug administration. *Rev Bras Psiquiatr* 2013;35(3):262–6. 480
- 440 [19] Goldman JM, Murr AS, Cooper RL. The rodent estrous cycle: characterization of 481
- 441 vaginal cytology and its utility in toxicological studies. *Birth Defects Res B: Dev 482*
- 442 *Reprod Toxicol* 2007;80:84–97. 483
- 443 [20] Roesler R, Walz R, Quevedo J, de-Paris F, Zanata SM, Graner E, Izquierdo I, et al. 484
- 444 Normal inhibitory avoidance learning and anxiety, but increased locomotor 485
- 445 activity in mice devoid of PrP(C). *Brain Res Mol Brain Res* 1999;71:349–53. 486
- 446 [21] Wells CE, Krikke B, Saunders J, Whittington A, Lever C. Changes to open field 487
- 447 surfaces typically used to elicit hippocampal remapping elicit graded explor- 488
- 448 atory responses. *Behav Brain Res* 2009;197:234–8. 489
- 449 [22] Silveira PP, Portella AK, Clemente Z, Gamaro GD, Dalmaz C. The effect of 490
- 450 neonatal handling on adult feeding behavior is not an anxiety-like behavior. 491
- 451 *Int J Dev Neurosci* 2005;23:93–9. 492
- 452 [23] Spruijt BM, van Hooff JA, Gispen WH. Ethology and neurobiology of grooming 493
- 453 behavior. *Physiol Rev* 1992;72:825–52. 494
- 454 [24] Lynn DA, Brown GR. The ontogeny of exploratory behavior in male and female 495
- 455 adolescent rats (*Rattus norvegicus*). *Dev Psychobiol* 2009;51:513–20. 496
- 456 [25] Porsolt RD, Anton G, Blavet N, Jalfre M. Behavioural despair in rats: a new model 497
- 457 sensitive to antidepressants treatments. *Eur J Pharmacol* 1978;47:379–91. 498
- 458 [26] Yang C, Li X, Wang N, Xu S, Yang J, Zhou Z. Tramadol reinforces antidepressant 499
- 459 effects of ketamine with increased levels of brain-derived neurotrophic factor 500
- 460 and tropomyosin-related kinase B in rat hippocampus. *Front Med* 2012;6(4): 501
- 461 411–5. 502
- 462 [27] Walf AA, Frye CA. A review and update of mechanisms of estrogen in the 503
- 463 hippocampus and amygdala for anxiety and depression behavior. *Neuropsychopharmacology* 2006;31:1097–111. 504
- 464 [28] Díaz-Véliz G, Butrón S, Benavides MS, Dussaubat N, Gender Mora S. estrous 505
- 465 cycle, ovariectomy, and ovarian hormones influence the effects of diazepam 506
- 466 on avoidance conditioning in rats. *Pharmacol Biochem Behav* 2000;66(4): 507
- 467 887–92. 508
- 468 [29] Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime 509
- 469 prevalence and age-of-onset distributions of DSM-IV disorders in the National 510
- 470 Comorbidity Survey Replication. *Arch Gen Psychiatry* 2005;62:593–602. 511
- 471 [30] Walf AA, Paris JJ, Frye CA. Chronic estradiol replacement to aged female rats 512
- 472 reduces anxiety-like and depression-like behavior and enhances cognitive 513
- 473 performance. *Psychoneuroendocrinology* 2009;34:909–16. 514
- 474 [31] Markowska AL. Sex dimorphisms in the rate of age-related decline in spatial 515
- 475 memory: relevance to alterations in the estrous cycle. *J Neurosci* 1999;19: 516
- 476 8122–33. 517
- 477 [32] Danilovich N, Sairam MR. Haploinsufficiency of the follicle-stimulating hor- 518
- 478 mone receptor accelerates oocyte loss inducing early reproductive senescence 519
- 479 and biological aging in mice. *Biol Reprod* 2002;67:361–9. 520
- 480 [33] Merchenthaler I, Lane MV, Numan S, Dellovade TL. Distribution of estrogen 481
- 482 receptor alpha and beta in the mouse central nervous system: in vivo autora- 483
- 484 diographic and immunocytochemical analyses. *J Comp Neurol* 2004;473: 485
- 486 270–91. 486
- 487 [34] Estrada-Camarena E, Fernández-Guasti A, López-Rubalcava C. Antidepressant- 487
- 488 like effect of different estrogenic compounds in the forced swimming test. 488
- 489 *Neuropsychopharmacology* 2003;28:830–8. 489
- 490 [35] Estrada-Camarena E, Fernández-Guasti A, López-Rubalcava C. Interaction 490
- 491 between estrogens and antidepressants in the forced swimming test in rats. 491
- 492 *Psychopharmacology (Berl)* 2004;173:139–45. 492
- 493 [36] Browne CA, Lucki I. Antidepressant effects of ketamine: mechanisms under- 493
- 494 lying fast-acting novel antidepressants. *Front Pharmacol* 2013;4:161. eCollection 494
- 495 2013. 495
- 496 [37] Carrier N, Kabbaj M. Sex differences in the antidepressant-like effects of 496
- 497 ketamine. *Neuropharmacology* 2013;70:27–34. 497
- 498 [38] Pillai AG, Anilkumar S, Chattarji S. The same antidepressant elicits contrasting 498
- 499 patterns of synaptic changes in the amygdala vs hippocampus. *Neuropsychopharmacology* 2012;37:2702–11. 499
- 500 [39] Lee SH, Mouradian MM. Up-regulation of D1A dopamine receptor gene 500
- 501 transcription by estrogen. *Mol Cell Endocrinol* 1999;156:151–7. 502
- 502 [40] Le Saux M, Di Paolo T. Influence of oestrogenic compounds on monoamine 503
- 504 transporters in rat striatum. *J Neuroendocrinol* 2006;18:25–32. 504
- 505 [41] Caddy C, Giaroli G, White TP, Shergill SS, Tracy DK. Ketamine as the prototype 505
- 506 glutamatergic antidepressant: pharmacodynamic actions, and a systematic 506
- 507 review and meta-analysis of efficacy. *Ther Adv Psychopharmacol* 2014;4: 507
- 508 75–99. 508
- 509 [42] McCarthy MM, Curran GH, Feder HH. Excitatory amino acid modulation of 509
- 510 lordosis in the rat. *Neurosci Lett* 1991;126(1):94–7. 510
- 511 [43] Frye CA, Petralia SM, Rhodes ME. Estrous cycle and sex differences in 511
- 512 performance on anxiety tasks coincide with increases in hippocampal pro- 512
- 513 gesterone and 3alpha,5alpha-THP. *Pharmacol Biochem Behav* 2000;67(3): 513
- 514 587–96. 514
- 515 [44] Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent 515
- 516 synapse formation underlies the rapid antidepressant effects of NMDA antago- 516
- 517 nists. *Science* 2010;329:959–64. 517
- 518 [45] Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, et al. NMDA receptor 518
- 519 blockade at rest triggers rapid behavioural antidepressant responses. *Nature* 519
- 520 2011; 15:475(7354):91–5. 520